InvestorsHub Logo
Followers 51
Posts 8986
Boards Moderated 1
Alias Born 10/25/2007

Re: Monksdream post# 11

Tuesday, 11/14/2023 9:16:54 AM

Tuesday, November 14, 2023 9:16:54 AM

Post# of 19
Cash runway extended through multiple data readouts and into Q1 of calendar 2025

MDNA11 is generally well tolerated and continues to demonstrate encouraging single-agent activity from Phase 1 portion of the ABILITY-1 Study including 100% and 70% reduction of target lesions in pancreatic and melanoma cancer patients, respectively

https://ir.medicenna.com/news-releases/news-release-details/medicenna-therapeutics-reports-second-quarter-fiscal-2024